Approximately 45.6% of Hispanics with metastatic non-small-cell lung cancer (NSCLC) harbor somatic STK11 or KEAP1 gene mutations without KRAS co-mutations or any other alterations, and around 15% had other concurrent mutations with KEAP1 or KRAS, supporting the potential key role of LKB1 as a contributor to lung cancer genesis in sporadic tumors [9]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.